Literature DB >> 16277025

Enhancement of the efficacy of chemotherapy with oxaliplatin plus 5-fluorouracil by pretreatment with IL-2 subcutaneous immunotherapy in metastatic colorectal cancer patients with lymphocytopenia prior to therapy.

P Lissoni1, F Brivio, L Fumagalli, G Di Fede, G Brera.   

Abstract

The present study was carried out to evaluate the influence of a short-period IL-2 administration on the efficacy of chemotherapy in metastatic colorectal cancer patients with pretreatment lymphocytopenia, which was defined as a lymphocyte count of less than 1500/mm3. The study included 144 consecutive metastatic colorectal cancer patients, who underwent chemotherapy with oxaliplatin plus 5-fluorouracil. Lymphocytopenia was seen in 41/144 (28%) patients, who were randomized to receive chemotherapy alone or chemotherapy after a prechemoimmunotherapy with IL-2 (3 MIU twice/day for 3 consecutive days), whereas patients with a normal pretreatment lymphocyte count received only chemotherapy. A normalization of the lymphocyte number was achieved in 12/19 lymphocytopenic patients pretreated with IL-2. The objective tumor regression rate achieved in patients with a normal lymphocyte count prior to chemotherapy was significantly higher compared to that obtained in lmphocytopenic patients treated with chemotherapy alone (54/103 vs. 3/22, p < 0.01), whereas no significant difference occurred between patients with normal lymphocyte count and lymphocytopenic patients pretreated with IL-2 (54/103 vs. 8/19). This study confirms that pretreatment lymphocytopenia is associated with reduced efficacy of chemotherapy in metastatic colorectal cancer patients. Moreover, it suggests that pretreatment with IL-2 before the onset of chemotherapy may enhance the efficacy of chemotherapy in lymphocytopenic patients. Therefore, the administration of IL-2 before the onset of chemotherapy to improve the immune status of cancer patients may be considered as a new chemoimmunotherapeutic combination, which may be recommended in the treatment of advanced cancer patients, particularly in those with cancer-related immune alterations.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16277025

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  8 in total

1.  Prognostic Significance of Lymphocyte Counts in Colon Cancer Patients Treated with FOLFOX Chemotherapy.

Authors:  O Kyu Noh; Seung Yeop Oh; Young Bae Kim; Kwang Wook Suh
Journal:  World J Surg       Date:  2017-11       Impact factor: 3.352

2.  The impact of the preoperative peripheral lymphocyte count and lymphocyte percentage in patients with colorectal cancer.

Authors:  Yasuhito Iseki; Masatsune Shibutani; Kiyoshi Maeda; Hisashi Nagahara; Tatsuro Tamura; Go Ohira; Sadaaki Yamazoe; Kenjiro Kimura; Takahiro Toyokawa; Ryosuke Amano; Hiroaki Tanaka; Kazuya Muguruma; Kosei Hirakawa; Masaichi Ohira
Journal:  Surg Today       Date:  2016-10-25       Impact factor: 2.549

3.  In situ tumor vaccination with adenovirus vectors encoding measles virus fusogenic membrane proteins and cytokines.

Authors:  Dennis Hoffmann; Wibke Bayer; Oliver Wildner
Journal:  World J Gastroenterol       Date:  2007-06-14       Impact factor: 5.742

4.  Absolute lymphocyte count is associated with survival in ovarian cancer independent of tumor-infiltrating lymphocytes.

Authors:  Katy Milne; Cheryl Alexander; John R Webb; Winnie Sun; Kristy Dillon; Steve E Kalloger; C Blake Gilks; Blaise Clarke; Martin Köbel; Brad H Nelson
Journal:  J Transl Med       Date:  2012-02-27       Impact factor: 5.531

5.  The impact of chemotherapy-associated neutrophil/ lymphocyte counts on prognosis of adjuvant chemotherapy in colorectal cancer.

Authors:  Hong Chu-Yuan; Peng Jing; Wei Yi-Sheng; Peng He-Ping; Yang Hui; Zhao Chu-Xiong; Liang Guo-Jian; Wang Guo-Qiang
Journal:  BMC Cancer       Date:  2013-04-03       Impact factor: 4.430

6.  Anti-colorectal cancer effect of interleukin-2 and interferon-β fusion gene driven by carcinoembryonic antigen promoter.

Authors:  Yan Wang; Mengchun Wang; Yan Li
Journal:  Onco Targets Ther       Date:  2016-05-30       Impact factor: 4.147

7.  Pretreatment lymphopenia is an easily detectable predictive and prognostic marker in patients with metastatic esophagus squamous cell carcinoma receiving first-line chemotherapy.

Authors:  Furong Kou; Zhihao Lu; Jian Li; Xiaotian Zhang; Ming Lu; Jun Zhou; Xicheng Wang; Jifang Gong; Jing Gao; Jie Li; Yan Li; Lin Shen
Journal:  Cancer Med       Date:  2016-01-26       Impact factor: 4.452

Review 8.  Cytotoxic Immunity in Peripheral Nerve Injury and Pain.

Authors:  Alexander J Davies; Simon Rinaldi; Michael Costigan; Seog Bae Oh
Journal:  Front Neurosci       Date:  2020-02-21       Impact factor: 4.677

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.